Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate.
Pasmatzi
E
E
Monastirli
A
A
Matsouka
P
P
Tsambaos
D
D
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D004890:Erythema / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D010915:Pityriasis / Q000139:chemically induced* / Q000188:drug therapy; D011743:Pyrimidines / Q000009:adverse effects*
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D008775:Methylprednisolone